Loading...
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
INM’s FA Score shows that 1 FA rating(s) are green whileVTYX’s FA Score has 1 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
INM’s TA Score shows that 4 TA indicator(s) are bullish while VTYX’s TA Score has 4 bullish TA indicator(s).
INM (@Biotechnology) experienced а +12.04% price change this week, while VTYX (@Biotechnology) price change was +15.65% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +1.41%. For the same industry, the average monthly price growth was +2.86%, and the average quarterly price growth was +60.72%.
INM is expected to report earnings on Sep 20, 2024.
VTYX is expected to report earnings on Aug 12, 2024.
Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
INM | VTYX | INM / VTYX | |
Capitalization | 1.79M | 333M | 1% |
EBITDA | N/A | N/A | - |
Gain YTD | -29.111 | 101.619 | -29% |
P/E Ratio | N/A | N/A | - |
Revenue | N/A | N/A | - |
Total Cash | N/A | N/A | - |
Total Debt | N/A | N/A | - |
INM | ||
---|---|---|
OUTLOOK RATING 1..100 | 31 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 27 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | |
SMR RATING 1..100 | 97 | |
PRICE GROWTH RATING 1..100 | 80 | |
P/E GROWTH RATING 1..100 | 72 | |
SEASONALITY SCORE 1..100 | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
INM | VTYX | |
---|---|---|
RSI ODDS (%) | 1 day ago82% | 1 day ago90% |
Stochastic ODDS (%) | 1 day ago90% | 1 day ago90% |
Momentum ODDS (%) | 1 day ago86% | 1 day ago87% |
MACD ODDS (%) | 1 day ago79% | 1 day ago90% |
TrendWeek ODDS (%) | 1 day ago82% | 1 day ago86% |
TrendMonth ODDS (%) | 1 day ago90% | 1 day ago83% |
Advances ODDS (%) | 1 day ago87% | 2 days ago86% |
Declines ODDS (%) | 8 days ago90% | 10 days ago84% |
BollingerBands ODDS (%) | 1 day ago90% | N/A |
Aroon ODDS (%) | 1 day ago90% | 1 day ago87% |
1 Day | |||
---|---|---|---|
MFs / NAME | Price $ | Chg $ | Chg % |
GMVAX | 16.10 | N/A | N/A |
Goldman Sachs Small/Mid Cap Value A | |||
VGRIX | 75.99 | -0.12 | -0.16% |
JPMorgan US Value A | |||
WCMGX | 24.88 | -0.10 | -0.40% |
WCM Focused Global Growth Institutional | |||
JACBX | 15.79 | -0.08 | -0.50% |
JHancock Mid Cap Growth I | |||
FNDMX | 11.53 | -0.08 | -0.69% |
Fidelity Series Sust Non-US Dev Mrkt Fd |
A.I.dvisor tells us that INM and VTYX have been poorly correlated (+31% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that INM and VTYX's prices will move in lockstep.
Ticker / NAME | Correlation To INM | 1D Price Change % | ||
---|---|---|---|---|
INM | 100% | +3.55% | ||
VTYX - INM | 31% Poorly correlated | -5.02% | ||
CRDF - INM | 28% Poorly correlated | -2.94% | ||
PYPD - INM | 28% Poorly correlated | -2.82% | ||
GLPG - INM | 27% Poorly correlated | +0.27% | ||
CALC - INM | 23% Poorly correlated | +0.37% | ||
More |
A.I.dvisor indicates that over the last year, VTYX has been loosely correlated with AURA. These tickers have moved in lockstep 57% of the time. This A.I.-generated data suggests there is some statistical probability that if VTYX jumps, then AURA could also see price increases.
Ticker / NAME | Correlation To VTYX | 1D Price Change % | ||
---|---|---|---|---|
VTYX | 100% | +18.85% | ||
AURA - VTYX | 57% Loosely correlated | -4.00% | ||
AKRO - VTYX | 52% Loosely correlated | -1.61% | ||
KROS - VTYX | 43% Loosely correlated | -0.75% | ||
CHRS - VTYX | 39% Loosely correlated | -0.46% | ||
ZNTL - VTYX | 38% Loosely correlated | -0.13% | ||
More |